(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...
(Date:12/15/2009)... Belgium, December 15 , ... Designed to Evaluate the Ability of,Cardiopoietic Cells to ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in ... today that it has completed, two months ahead ... pivotal Phase II/III trial of C-Cure, a,unique stem ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2... BioForm Medical,Inc. (Nasdaq: BFRM ) today announced that ... at the upcoming 26th Annual,JPMorgan Healthcare Conference being held ... on Monday, January 7th, 2008 at 8:30,a.m. PST (11:30 ... San Francisco,CA., A live and archived copy of ...
... 19 Instrumentation Laboratory,(IL) today announced that ... with HealthTrust Purchasing Group, LP (HealthTrust), a,leading ... all Consorta,Inc. members. Consorta, another leading healthcare ... that established,Consorta as the sixth equity owner ...
... serious, hereditary ... bleeding disorder, found in region, KING OF PRUSSIA, Pa., ... Health and Medical Education (MOHME) has,granted rights to the company ... immediately. Haemate P is indicated for,the treatment of von Willebrand ...
Other Biology Technology:BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta 2CSL Behring Expands Into Middle East Market with Haemate(R) P 2CSL Behring Expands Into Middle East Market with Haemate(R) P 3Purified anti-eIF-4E...
Polyclonal Antibody to CLAN...
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products:Biology NavigationMedical Navigation